Document Detail


Antiplatelet and anticoagulant therapies in acute coronary syndromes.
MedLine Citation:
PMID:  20033270     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The combination of aspirin and clopidogrel is the mainstay antiplatelet therapy for acute coronary syndromes (ACS). However, the dosing of aspirin, the dosing of clopidogrel, the timing of clopidogrel initiation as well as the duration of clopidogrel therapy remain controversial matters. Clopidogrel resistance is an emerging concept with potential clinical implications. In the era of clopidogrel and bivalirudin, the role of glycoprotein IIb/IIIa antagonists is being challenged, yet they are still indicated in a select high-risk population. Concerning anticoagulant use in ACS, newer agents, bivalirudin and fondaparinux, have improved outcomes in comparison to heparin in patients managed with an invasive or conservative strategy, respectively. Combining multiple antiplatelet agents and an anticoagulant is the standard of care for ACS.
Authors:
Elias B Hanna; David Luke Glancy; Jorge F Saucedo
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  24     ISSN:  1573-7241     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-04-15     Completed Date:  2010-09-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  61-70     Citation Subset:  IM    
Affiliation:
Cardiology Department, Oklahoma University, Oklahoma City, 73190, USA. elias-hanna@ouhsc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / drug therapy*
Anticoagulants / administration & dosage,  adverse effects,  pharmacology,  therapeutic use*
Drug Therapy, Combination / methods,  trends
Humans
Platelet Aggregation Inhibitors / administration & dosage,  adverse effects,  pharmacology,  therapeutic use*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Platelet Aggregation Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Production of Synthetic Methionine-Free and Synthetic Methionine-Limited Alpha Casein: Protein Foods...
Next Document:  Extracting functional components of neural dynamics with Independent Component Analysis and inverse ...